相关实验视频
Updated: Jun 26, 2025

08:19
In Vitro Assessment of Cardiac Function Using Skinned Cardiomyocytes
Published on: June 22, 2020
6.4K
快速结合骨髓蛋白C蛋白的表达加剧了心力衰竭中的功能障碍
bioRxiv : the preprint server for biology
|May 15, 2024
概括
在心力衰竭期间心脏中快速骨肌蛋白结合蛋白-C (fMyBP-C) 的升高是一种病理反应,恶化心脏功能障碍. 移除fMyBP-C可以防止心力衰竭的发展,这表明它是治疗目标.
科学领域:
- 心血管生物学 心血管生物学
- 骨肌肉生理学 骨肌肉生理学
- 分子心脏病学分子心脏病学
背景情况:
- 心力衰竭涉及复杂的遗传和蛋白质重塑.
- 快速骨肌蛋白结合蛋白-C (fMyBP-C) 在患病的心脏中被上调,但其作用尚不清楚.
- 心脏肌蛋白结合蛋白-C (cMyBP-C) 和fMyBP-C共享同质性,但具有不同的功能.
研究的目的:
- 阐明改变fMyBP-C表达 (过度表达和淘汰赛) 的心脏后果.
- 为了确定fMyBP-C是否足以引起心脏功能障碍.
- 评估心力衰竭发育期间fMyBP-C的必要性.
主要方法:
- 产生特定于心脏的fMyBP-C过度表达小鼠模型.
- 交叉 fMyBP-C 过度表达小鼠与 cMyBP-C 零小鼠.
- 在fMyBP-C无小鼠中利用横向大动脉收缩 (TAC) 诱导心力衰竭.
- 在使用谱系追踪的各种心脏病模型中确认了fMyBP-C上调.
主要成果:
- 低水平的fMyBP-C表达诱导了轻度的心脏重塑和瘤瘤功能障碍.
- 独特的fMyBP-C表达在心力衰竭模型中加剧了心脏病理.
- 在TAC后,fMyBP-C无菌小鼠显示出对心力衰竭的显著保护.
- 肌肉蛋白超放松状态的不同调节可能是这些效应的基础.
结论:
- 患病心脏中的fMyBP-C升高是一种病理性,而不是补偿性反应.
- 准fMyBP-C上调可能为心力衰竭提供治疗策略.
- 了解fMyBP-C的作用,可以了解心脏病中的瘤功能.
相关概念视频
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Heart Failure Drugs: Inotropic Agents
573
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
573
Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
Pathophysiology of Cardiac Performance
644
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
644
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
141
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
141

